外科主动脉瓣置换术后新发术后心房颤动与长期结局的关联
这项回顾性、人群为基础的研究纳入瑞典2007-2017年无术前心房颤动的单纯外科主动脉瓣置换术患者7038例和联合冠状动脉旁路移植术患者3854例,发现术后新发心房颤动在两组分别占44.5%和50.7%,并与长期死亡、缺血性卒中、复发性心房颤动和心力衰竭住院风险升高相关;早期启用口服抗凝药未与死亡、缺血性卒中或血栓栓塞风险降低相关。
要点
- 单纯外科主动脉瓣置换术后新发心房颤动与长期死亡风险升高相关(aHR 1.21)。
- 联合手术组术后新发心房颤动与死亡风险升高相关(aHR 1.31),但与缺血性卒中无显著关联。
- 早期启用口服抗凝药未与死亡、缺血性卒中或血栓栓塞风险降低相关。
核心结论
- 外科主动脉瓣置换术后新发术后心房颤动与长期死亡率和发病率风险升高相关。
- 需要进一步研究以明确口服抗凝药在外科主动脉瓣置换术后新发术后心房颤动患者中的作用。
研究设计与样本
- 回顾性、人群为基础的研究,纳入瑞典2007-2017年无术前心房颤动的单纯外科主动脉瓣置换术患者7038例和联合外科主动脉瓣置换术+冠状动脉旁路移植术患者3854例。
- 个体患者数据来自4个全国性登记数据库合并。
- 在单纯外科主动脉瓣置换术和联合手术患者中分别采用逆概率处理加权调整的Cox回归模型。
- 中位随访时间为4.7年(范围0-10年)。
主要发现
- 术后新发心房颤动在单纯外科主动脉瓣置换术患者中占44.5%,在联合手术患者中占50.7%。
- 在单纯外科主动脉瓣置换术患者中,术后新发心房颤动与长期死亡风险升高相关(aHR 1.21,95%CI 1.06-1.37),与缺血性卒中风险升高相关(aHR 1.32,95%CI 1.08-1.59),并与任何血栓栓塞、心力衰竭住院和复发性心房颤动相关。
- 在联合手术患者中,术后新发心房颤动与死亡风险升高相关(aHR 1.31,95%CI 1.14-1.51),与复发性心房颤动和心力衰竭相关,但与缺血性卒中无显著关联(aHR 1.04,95%CI 0.84-1.29),与血栓栓塞也无显著关联。
- 出院后30天内,单纯外科主动脉瓣置换术和联合手术患者中伴有术后新发心房颤动者分别有67.0%和65.9%领取了口服抗凝药。
- 早期启用口服抗凝药在任何一组患者中均未与死亡、缺血性卒中或血栓栓塞风险降低相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data on prognostic implications of new-onset postoperative atrial fibrillation (POAF) after surgical aortic valve replacement (SAVR) is limited. We sought to explore associations between POAF, early initiated oral anticoagulation (OAC) and long-term outcome after SAVR and combined SAVR + coronary artery bypass grafting (CABG). METHODS: This is a retrospective, population-based study including all isolated SAVR (n = 7038) and combined SAVR and CABG patients (n = 3854) without a history of preoperative atrial fibrillation (AF) in Sweden 2007-2017. Individual patient data were merged from 4 nationwide registries. Inverse probability of treatment weighting-adjusted Cox regression models were employed separately in SAVR and SAVR + CABG patients. The median follow-up time was 4.7 years (range 0-10 years). RESULTS: POAF occurred in 44.5% and 50.7% of SAVR and SAVR + CABG patients, respectively. In SAVR patients, POAF was associated with increased long-term risk of death [adjusted hazard ratio (aHR) 1.21 (95% confidence interval 1.06-1.37)], ischaemic stroke [aHR 1.32 (1.08-1.59)], any thromboembolism, heart failure hospitalization and recurrent AF. In SAVR + CABG, POAF was associated with death [aHR 1.31 (1.14-1.51)], recurrent AF and heart failure, but not with ischaemic stroke [aHR 1.04 (0.84-1.29)] or thromboembolism. OAC was dispensed within 30 days after discharge to 67.0% and 65.9%, respectively, of SAVR and SAVR + CABG patients with POAF. Early initiated OAC was not associated with reduced risk of death, ischaemic stroke or thromboembolism in any group of patients. CONCLUSIONS: POAF after SAVR is associated with an increased risk of long-term mortality and morbidity. Further studies are warranted to clarify the role of OAC in SAVR patients with POAF.
引用
- Rezk M, Taha A, Nielsen SJ, et al. Associations between new-onset postoperative atrial fibrillation and long-term outcome in patients undergoing surgical aortic valve replacement. Eur J Cardiothorac Surg. 2023. PMID: 36961335. doi:10.1093/ejcts/ezad103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。